Skip to main content

March 27, 2017

Multiple Chronic Conditions (MCCs) Feature

Identify Multiple Chronic Condition (MCC) guidelines in NGC by searching or browsing, and then applying the "Addresses Multiple Chronic Conditions" filter from the left side of the Search Results page. Learn more.

NGC Spotlight

Visit the updated AHRQ Evidence Reports page for a listing of reports produced under AHRQ's Evidence-based Practice Program and Effective Health Care Program.

U.S. Food and Drug Administration (FDA) Advisory

March 15, 2017: Viberzi (eluxadoline) External Web Site Policy: FDA is warning that Viberzi (eluxadoline), a medicine used to treat irritable bowel syndrome with diarrhea (IBS-D), should not be used in patients who do not have a gallbladder. An FDA review found these patients have an increased risk of developing serious pancreatitis that could result in hospitalization or death. Pancreatitis may be caused by spasm of a certain digestive system muscle in the small intestine. As a result, FDA is working with the Viberzi manufacturer, Allergan, to address these safety concernsars.

Health Awareness Topics: March 2017

How to Participate

Submit Guidelines: Visit our Submit Guidelines page for information on how to submit your organization's guidelines.

Suggest a Guideline for Possible Inclusion: Submit your suggestions for evidence-based clinical practice guidelines that you would like to see included in NGC.

NGC's Sister Resource

Look for Quality Measures in AHRQ's National Quality Measures Clearinghouse (NQMC) External Web Site Policy.